Sustained virologic response decreases serum markers of angiogenesis, inflammation, and fibrosis in HIV/HCV-coinfected patients on hepatitis C virus therapy

AIDS Patient Care and STDs

Volumn 25, Issue 3, 2011, Pages 131-133

  García Álvarez, Mónica ^a   Berenguer, Juan ^b   Micheloud, Dariela ^a,b   Guzmán Fulgencio, María ^a   Catalán, Pilar ^b   López, Juan Carlos ^b   Cosín, Jaime ^b   Miralles, Pilar ^b   Carrero Gras, Ana ^b   Resino, Salvador ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HYALURONIC ACID; INTERFERON; LEPTIN; RIBAVIRIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR RECEPTOR 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ANGIOGENESIS; ANTIVIRAL THERAPY; CLINICAL ARTICLE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; LETTER; LIVER FIBROSIS; MALE; MIXED INFECTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INFLAMMATION; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RETROSPECTIVE STUDIES; RIBAVIRIN;

EID: 79952514298     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2010.0387     Document Type: Letter

References (17)

1. Mendes-Correa MC, Widman A, Brussi ML, Guastini CF, Gianini RJ. Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C in Brazil. AIDS Patient Care STDs 2008;22:701-707.
2. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis 2001;33:562-569. (Pubitemid 32709592)
3. Scott JD, Wald A, Kitahata M, et al. Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population. AIDS Patient Care STDs 2009;23:925-929.
4. Pol S, Soriano V. Management of chronic hepatitis C virus infection in HIV-infected patients. Clin Infect Dis 2008;47:94-101. (Pubitemid 351920593)
5. Aronsohn A, Reau N. Long-term outcomes after treatment with interferon and ribavirin in HCV patients. J Clin Gastroenterol 2009;43:661-671.
6. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002;36(5 Suppl 1): S152-160. (Pubitemid 35253476)
7. Kelleher TB, Afdhal N. Assessment of liver fibrosis in coinfected patients. J Hepatol 2006;44(Suppl 1): S126-S31.
8. Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J. Angiogenesis in liver disease. J Hepatol 2009;50:604-620.
9. Itoh Y, Okanoue T, Ohnishi N, et al. Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1999;94:1332-1340. (Pubitemid 29214650)
10. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 1995;54:1-8.
11. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-218. (Pubitemid 40385459)
12. Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF, et al. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: A paired liver biopsy study. J Hepatol 2007;46:613-619. (Pubitemid 46402952)
13. Resino S, Micheloud D, Miralles P, et al. Diagnosis of advanced fibrosis in HIV and hepatitis C virus-coinfected patients via a new noninvasive index: The HGM-3 index. HIV Med 2010;11:64-73.
14. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009;50:957-969.
15. Fontana RJ, Bonkovsky HL, Naishadham D, et al. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol 2009;7:219-226.
16. Vespasiani-Gentilucci U, Galati G, Mazzarelli C, et al. Angiogenic cytokines in patients undergoing antiviral treatment for chronic hepatitis C virus infection. J Interferon Cytokine Res (in press).
17. Zografos TA, Rigopoulou EI, Liaskos C, et al. Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis. J Hepatol 2006;44:848-855.